title: Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.
abstract: BACKGROUND
  Epidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic side effects in the majority of patients, and guidelines are crucial for the prevention and treatment of these untoward events. The purpose of this panel was to develop evidence-based recommendations for EGFRI-associated dermatologic toxicities.
  
  
  METHODS
  A multinational, interdisciplinary panel of experts in supportive care in cancer reviewed pertinent studies using established criteria in order to develop first-generation recommendations for EGFRI-associated dermatologic toxicities.
  
  
  RESULTS
  Prophylactic and reactive recommendations for papulopustular (acneiform) rash, hair changes, radiation dermatitis, pruritus, mucositis, xerosis/fissures, and paronychia are presented, as well as general dermatologic recommendations when possible.
  
  
  CONCLUSIONS
  Prevention and management of EGFRI-related dermatologic toxicities is critical to maintain patients' health-related quality of life and dose intensity of antineoplastic regimens. More rigorous investigation of these toxicities is warranted to improve preventive and treatment strategies.
authors.affiliation: Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Rockefeller Outpatient Pavilion Suite 228, 160 East 53rd Street, New York, NY 10022, USA. lacoutuM@mskcc.org
authors.forename: Mario E
authors.initials: ME
authors.lastname: Lacouture
authors.forename: Milan J
authors.initials: MJ
authors.lastname: Anadkat
authors.forename: René-Jean
authors.initials: RJ
authors.lastname: Bensadoun
authors.forename: Jane
authors.initials: J
authors.lastname: Bryce
authors.forename: Alexandre
authors.initials: A
authors.lastname: Chan
authors.forename: Joel B
authors.initials: JB
authors.lastname: Epstein
authors.forename: Beth
authors.initials: B
authors.lastname: Eaby-Sandy
authors.forename: Barbara A
authors.initials: BA
authors.lastname: Murphy
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005076:Exanthema / Q000139:chemically induced / Q000517:prevention & control / Q000628:therapy; D006801:Humans; D038622:Internationality; D017410:Practice Guidelines as Topic; D011537:Pruritus / Q000139:chemically induced; D012871:Skin Diseases / Q000139:chemically induced* / Q000517:prevention & control / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents; D066246:ErbB Receptors